Novasight Hybrid System
Commercial- Indications
- Coronary artery imaging
Company intelligence / Profile preview
The Novasight Hybrid System combines intravascular ultrasound and optical coherence tomography to provide simultaneous, co-linear imaging of coronary arteries. It has received regulatory approvals from the US FDA, Health Canada, China’s NMPA, and Japan’s MHLW. The next-generation AI-enhanced version aims for further clinical adoption. Clinical use includes improved visualization for plaque burden assessment, stent sizing/assessment, calcified lesions, restenosis/thrombus evaluation. The Foresight ICE system provides advanced intracardiac echocardiography with both side and forward viewing capabilities. Over fifty clinical cases have been performed with the ICE system.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Conavi Medical.